Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biohaven’s Migraine Empire Expands As Zavegepant Conquers Phase III

Second Drug Is Market’s First Intranasal CGRP Inhibitor

Executive Summary

The company will seek US FDA approval after intranasally administered zavegepant passes its second pivotal test in the treatment of migraine attacks, followed by ex-US approvals with partner Pfizer. 

You may also be interested in...



Biohaven Gets Pfizer’s Help To Make Nurtec An Ex-US Success Story Too

As the only oral CGRP migraine therapy approved for both prevention and acute therapy, Nurtec has taken significant US market share. Biohaven will call on Pfizer’s expertise and contacts to repeat that success abroad.

AbbVie Ready To Leverage Migraine Franchise In Crowded Market

The US FDA approved the oral CGRP inhibitor Qulipta (atogepant) for migraine prevention, making AbbVie the only company with three drugs for three different migraine indications.

Biohaven Pursues Best-In-Class Sales With Nurtec ODT’s Migraine Prevention Approval

CEO Vlad Coric said the customizable use of Nurtec ODT to stop and prevent migraine attacks is a differentiating factor that will help it go up against big pharma competitors.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC145539

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel